TargEDys announces the publication of the first double-blind, randomized, placebo-controlled clinical trial showing Hafnia alvei's efficacy
TargEDys announces the publication of the first double-blind, randomized, placebo-controlled clinical trial showing Hafnia alvei's efficacy at an unprecedented level in weight loss and satiety
PR89977
LONGJUMEAU, France, June 08, 2021 /PRNewswire=KYODO JBN/ --
The French biotech TargEDys specialized in breakthrough microbiome-based
solutions announces the publication of its study conducted in 230 overweight
adults supplemented for 12 weeks, confirming the efficacy of the precision
probiotic Hafnia alvei HA4597(R) to improve weight loss, hip circumference
reduction and metabolic parameters thanks to the action of the probiotic and
its postbiotic ClpB on feeling of fullness.
Mechanistic and preclinical studies showed Hafnia alvei is able to produce
Caseinolytic peptidase B, a protein mimicking the hormone of satiety alpha-MSH,
and to reduce food intake in murine models of obesity. These new results
confirm the efficacy of this PreciBiomic(TM) strain in supporting feeling of
fullness and weight loss in overweight subjects, as well as reducing hip
circumference and glycemia.
With an average of 3,6% weight loss in 12 weeks in the probiotic group,
Hafnia alvei is dramatically more effective than any other probiotic studied in
weight management, and this level of impact fills the gap between the sectors
of food supplements and drugs. It also drives innovation in the probiotics
field, shifting the approach to precision probiotics, with enhanced efficacy
thanks to the precise understanding of the molecular mechanism of action.
Hafnia alvei can be found in the products EnteroSatys(R) and Satylia(R) in
France, Portugal, Italy and Slovenia, and TargEDys is looking for distribution
partners to make this breakthrough solution for the prevention of obesity
available to consumers worldwide.
Grégory Lambert, CEO of TargEDys, declares:
"This will be a game-changer in the sector of weight management, with
finally a solution that meets consumers expectations in terms of safety and
naturality, while also bringing a real, demonstrated efficacy based on
molecular mimicry and the biochemical regulation of appetite."
About TargEDys(R)
TargEDys(R) is a commercial-stage French biotech specialized in the
development of nutraceutical solutions for the control of appetite through
microbiome interventions. The company is the fruit of 15 years of research on
the microbiota conducted within academic laboratories. The company developed
and started the commercialization of its first product based on the PreciBiomic
strain Hafnia alvei HA4597(TM) and develops a product portfolio focusing on
overweight, undernutrition and mental health, all based on the concept of
precibiomic strains backed by a molecular mechanism of action and in vivo
studies.
More information at www.targedys.com
Contact: Arnaud Faure & Nina Vinot; bd@targedys.com
Logo: https://mma.prnewswire.com/media/1528261/Targedys_Logo.jpg
Source: TargEDys
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。